Ilan Shimon

3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial

Carel W. le Roux, Arne Astrup, Ken Fujioka et al. · The Lancet · 2017 · 813 citations

Obesity, Metabolic Syndrome, Nutrition +8

Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial

Stefano Del Prato, Steven E. Kahn, Imre Pávó et al. · The Lancet · 2021 · 586 citations

Metabolic Syndrome, Diabetes Management, Cardiovascular Disease +9

Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial

Mônica R. Gadelha, Marcello D. Bronstein, Thierry Brue et al. · The Lancet Diabetes & Endocrinology · 2014 · 395 citations

Medicine, Neurology, Pasireotide Versus

Low Albumin Levels Are Associated with Mortality Risk in Hospitalized Patients

Amit Akirov, Hiba Masri‐Iraqi, Alaa Atamna et al. · The American Journal of Medicine · 2017 · 343 citations · Full text

Hospitalization, Disease Progression, Acute Care +8

A Consensus on the Diagnosis and Treatment of Acromegaly Comorbidities: An Update

Andrea Giustina, Ariel Barkan, Albert Beckers et al. · The Journal of Clinical Endocrinology & Metabolism · 2019 · 342 citations · Full text